Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Percheron TherapeuticsPERCF Cash-to-Debt is 423.00 as of Dec. 2025, which is 23% above its 10-year median of 343.88. The stock has 2 warning signs investors should review. Among 982 Drug Manufacturers companies, Percheron Therapeutics ranks better than 92.16% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Percheron Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2025 was 423.00.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Percheron Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Dec. 2025.
The historical rank and industry rank for Percheron Therapeutics's Cash-to-Debt or its related term are showing as below:
PERCF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 19.67 Med: 343.88 Max: No Debt
Current: 405.09
During the past 13 years, Percheron Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 19.67. And the median was 343.88.
PERCF's Cash-to-Debt is ranked better than 92.16% of 982
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs PERCF: 405.09
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Percheron Therapeutics Cash-to-Debt Related Terms
Percheron Therapeutics Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Percheron Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Percheron Therapeutics Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Percheron Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Percheron Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Percheron Therapeutics (PERCF) has a Cash-to-Debt of 423.00 as of Dec. 2025. This is 23% above median its historical median of 343.88. Over the past decade, Percheron Therapeutics' Cash-to-Debt has ranged from 19.67 to 10,000.00. According to the industry distribution chart, Percheron Therapeutics ranks #77 out of 982 companies in the Drug Manufacturers industry, placing it in the top 7.8%.
Is Percheron Therapeutics' Cash-to-Debt too high?
Percheron Therapeutics' current Cash-to-Debt of 423.00 is 23% above median its 10-year median of 343.88. Over the past 10 years, this metric has ranged from a low of 19.67 to a high of 10,000.00. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Percheron Therapeutics' value of 423.00 is 43063.3% above this industry median. Based on the distribution chart, Percheron Therapeutics ranks #77 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does Percheron Therapeutics' Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Percheron Therapeutics ranks #77 out of 982 companies for Cash-to-Debt. This places Percheron Therapeutics in the top 8% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.98. Percheron Therapeutics' value of 423.00 is 43063.3% above this benchmark. Historically, Percheron Therapeutics' own Cash-to-Debt has ranged from 19.67 to 10,000.00 over the past decade. While the company's 10-year median is 343.88 vs. the industry median of 0.98, Percheron Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Percheron Therapeutics's current Cash-to-Debt of 423.00 is 43063.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Percheron Therapeutics's current Cash-to-Debt is 423.00, which is 23% above median its own 10-year median of 343.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Percheron Therapeutics stock overvalued right now?
Percheron Therapeutics (PERCF) has a current Cash-to-Debt of 423.00. The current Cash-to-Debt is 423.00, which is 23% above median its 10-year median of 343.88 and 43063.3% above the Drug Manufacturers industry median of 0.98. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Percheron Therapeutics (PERCF), the current Cash-to-Debt is 423.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Percheron Therapeutics Ltd is a biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The company operates into two operating segment: ATL1102 and ATL1103. Key revenue is generated from ATL1102.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PERCF has been successfully added to your 
